Agilent Technologies, BioTrove to Streamline Drug Discovery Using High-Throughput Mass Spectrometry
News Nov 03, 2008
Agilent Technologies Inc. and BioTrove have announced that they have signed a non-exclusive value-added reseller agreement to enable BioTrove to provide an end-to-end solution for mass spectrometry-based drug discovery. This solution will combine technology leader BioTrove’s RapidFire Mass Spectrometry sample preparation system with Agilent’s mass spectrometers.
The reseller agreement expands on an established strategic relationship between Agilent and BioTrove, furthering both companies’ ability to enhance customer workflows.
BioTrove will provide an integrated solution for drug discovery using mass spectrometry analysis, affording customers access to a single system. BioTrove’s RapidFire system; comprised of microfluidic handling for sample preparation and advanced software; combined with Agilent’s Triple Quadrupole and Time-of-Flight mass spectrometry instruments create a high-throughput advanced workflow solution.
The agreement includes Agilent atmospheric pressure ionization sources with the mass spectrometers, which generate quantitative and qualitative results via sensitive and selective mass analysis, based on the molecular composition of the target compounds.
RapidFire mass spectrometry decreases the bottleneck that occurs during high-throughput screening of candidate drug compounds by enabling automated sample preparation, at a rate of approximately six to eight seconds per sample, followed by seamless integration with the mass spectrometer.